Stockreport

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01 [Yahoo! Finance]

ATAI Life Sciences N.V. - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF VLS-01 is being developed as a rapid-acting and durable antidepressant for treatment resistant depression, which affects approximately 100 million people globally VLS [Read more]